Department of Laboratory Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain.
Department of Laboratory Hematology, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain.
Cytometry B Clin Cytom. 2018 Jan;94(1):136-142. doi: 10.1002/cyto.b.21509. Epub 2017 Jan 25.
CD43 has been used on histological samples for the differential diagnosis of lymphoproliferative disorders but there is scarce data on its use by flow cytometry (FC). We set out to characterize the expression of CD43 by FC in B-cell lymphoproliferative disorders and to determine its possible role in the differential diagnosis of these malignancies.
We analyzed the expression of CD43 in clonal B-cell lymphoproliferative disorders with exclusive peripheral blood and/or bone marrow involvement based on their Moreau chronic lymphocytic leukemia (CLL) score with particular emphasis on Moreau CLL score 3 (MS3) cases, which often present a diagnostic challenge. The cohort included 433 CLL (score 4-5), 34 MS3 and 166 lymphoproliferative disorders with lower scores.
Generally, the higher the Moreau CLL score, the higher CD43-positivity (425/443 [96%] for CLL, 23/34 [67%] for MS3 and 18/166 [11%] for cases with lower scores). MS3 cases constituted 5.4% of all cases and were more frequently CD5, CD200, CD43-positive and had del(q13) than score 0-2 cases. Among MS3 cases, del(13q) cases were predominantly CD43-positive (12/13).
The frequency of CD43-positivity increases sharply with the Moreau score. MS3 cases seem to include both CLL and non-CLL lymphoproliferative disorders and CD43 could aid in the differential diagnosis between the two. However, studies analyzing the correlation between CD43 expression and the underlying biologic changes of these cases are warranted. © 2017 International Clinical Cytometry Society.
CD43 已被用于组织学样本，用于辅助鉴别诊断淋巴增殖性疾病，但在流式细胞术（FC）中使用的相关数据很少。我们旨在通过 FC 对 B 细胞淋巴增殖性疾病中 CD43 的表达进行特征描述，并确定其在这些恶性肿瘤鉴别诊断中的可能作用。
我们根据莫罗慢性淋巴细胞白血病（CLL）评分分析了仅累及外周血和/或骨髓的克隆性 B 细胞淋巴增殖性疾病中 CD43 的表达，特别强调莫罗 CLL 评分 3（MS3）病例，因为此类病例的诊断通常具有挑战性。该队列包括 433 例 CLL（评分 4-5）、34 例 MS3 和 166 例评分较低的淋巴增殖性疾病。
通常，莫罗 CLL 评分越高，CD43 阳性率越高（443 例中有 425 例[96%]，34 例中有 23 例[67%]，评分较低的 166 例中有 18 例[11%]）。MS3 病例占所有病例的 5.4%，与评分 0-2 病例相比，MS3 病例更常为 CD5、CD200、CD43 阳性，并具有 del(q13)。在 MS3 病例中，del(13q)病例主要为 CD43 阳性（13 例中有 12 例）。
CD43 阳性率随莫罗评分急剧增加。MS3 病例似乎既包括 CLL 也包括非 CLL 淋巴增殖性疾病，并且 CD43 可能有助于两者之间的鉴别诊断。然而，有必要开展分析这些病例中 CD43 表达与潜在生物学变化之间相关性的研究。© 2017 年国际临床细胞化学协会。
